fashion -WSS

fashion

author：fashion 2025-10-02 18:05:29 - browse：48543

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Wikipedia

WSS

A preacher's new calling: Diversifying neuroscience research

The EPA's new lead rule: How one expert crunched the numbers

Despite FDA concern, risk that CAR

ReNAgade cuts staff seven months after raising $300 million

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Life science postdocs should get big pay hike, NIH panel says

explore

fashion

entertainment

Apple is now the first public company to be valued at $3 trillion

Organ aging and disease risk measured by new blood test

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Apple is now the first public company to be valued at $3 trillion

FDA early review: GLP

Cancer drug shortages should be causing more outrage

U.K. Biobank has 500,000 peoples' genome sequences available

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The EPA's new lead rule: How one expert crunched the numbers

explore

Mayo Clinic plans $5B tech

Life science postdocs should get big pay hike, NIH panel says

Physician assistants need a new name. Here's what it should be

Physician assistants need a new name. Here's what it should be

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Male doctors called my cancer incurable. A female doctor showed it wasn't

hotspot

Wikipedia

leisure time

leisure time